Induced Pluripotent Stem Cell (iPSC) Global Industry Report 2024 - Revolutionizing Medicine: The Transformative Power and Commercial Potential of Induced Pluripotent Stem Cells (iPSCs)
August 16, 2024 10:44 ET
|
Research and Markets
Dublin, Aug. 16, 2024 (GLOBE NEWSWIRE) -- The "Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, and Forecasts, 2024" report has been added to ResearchAndMarkets.com's...
Microcarrier Market Report 2024-2032 Featuring Manufacturing Specialists - Thermo Fisher Scientific, Eppendorf, Danaher, Sartorius, Bio-Rad Laboratories, Corning, Lonza, Getinge and BD and Co
August 16, 2024 10:33 ET
|
Research and Markets
Dublin, Aug. 16, 2024 (GLOBE NEWSWIRE) -- The "Global Microcarrier Market Report By Applicati, End User, Countries and Company Analysis 2024-2032" report has been added to ResearchAndMarkets.com's...
Longeveron® Announces Second Quarter 2024 Financial Results and Provides Business Update
August 14, 2024 16:05 ET
|
Longeveron
Longeveron reports Q2 2024 financial results and provides business update. Phase 2b clinical trial in HLHS achieves 70% enrollment.
Advanced Therapy Medicinal Products Global Strategic Business Report 2023-2030: Rising Demand for Gene Therapy Spurs Market Expansion, North America and Europe Dominate
August 13, 2024 11:06 ET
|
Research and Markets
Dublin, Aug. 13, 2024 (GLOBE NEWSWIRE) -- The "Advanced Therapy Medicinal Products - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market...
Meso Numismatics, a Renowned Leader in Regenerative Medical, Announces Global Stem Cells Groups (GSCG) Launch of Revolutionary New Line of Peptides
August 13, 2024 06:33 ET
|
Meso Numismatics, Inc.
LAS VEGAS, NV, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Meso Numismatics, Inc. (“Meso Numismatics” or the “Company”) (MSSV), a renowned leader in regenerative medical company, and in the process with FINRA...
Longeveron® to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024
August 05, 2024 16:05 ET
|
Longeveron
Longeveron announced that it will report Q2 2024 financial results and provide a business update on Wednesday, August 14, 2024.
Exosome Diagnostics and Therapeutics Research Report 2024: Market to Grow at a Staggering CAGR of 81.2% by 2032
August 02, 2024 10:48 ET
|
Research and Markets
Dublin, Aug. 02, 2024 (GLOBE NEWSWIRE) -- The "Global Exosome Diagnostics and Therapeutics Market by Type (Diagnostics, Therapeutics), Product & Service (Instruments, Kits, Reagents), Source...
NurExone Announces the Transfer of Manufacturing of the Active Element in ExoPTEN Drug to a Commercial GMP Manufacturer
August 01, 2024 16:04 ET
|
NurExone Biologic Inc
NurExone Announces the Transfer of Manufacturing of the Active Element in ExoPTEN Drug to a Commercial GMP Manufacturer
Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s Association International Conference® (AAIC)
July 28, 2024 16:51 ET
|
Longeveron
Longeveron Phase 2a clinical results in Alzheimer's Disease selected for Featured Research oral presentation at Alzheimer’s Association International Conf
Tissue Engineering Market Size is Expected to Reach USD 12.43 Billion by 2032, Growing at a CAGR of 14.40%: Straits Research
July 18, 2024 10:20 ET
|
Straits Research Private Limited - Garner Insights
New York, United States, July 18, 2024 (GLOBE NEWSWIRE) -- As per the Latest Report by Straits Research, the global tissue engineering market size was valued at USD 4,333.61 million in 2023. It is...